Search

Your search keyword '"Candalija A"' showing total 5 results
Start Over Author "Candalija A" Publisher mdpi ag
5 results on '"Candalija A"'

1. The State of the Art and Challenges of In Vitro Methods for Human Hazard Assessment of Nanomaterials in the Context of Safe-by-Design

Author

Nienke Ruijter, Lya G. Soeteman-Hernández, Marie Carrière, Matthew Boyles, Polly McLean, Julia Catalán, Alberto Katsumiti, Joan Cabellos, Camilla Delpivo, Araceli Sánchez Jiménez, Ana Candalija, Isabel Rodríguez-Llopis, Socorro Vázquez-Campos, Flemming R. Cassee, and Hedwig Braakhuis

Subjects
nanomaterials, safe-by-design, hazard testing, in vitro methods, SAbyNA, advanced materials, Chemistry, QD1-999
Abstract

The Safe-by-Design (SbD) concept aims to facilitate the development of safer materials/products, safer production, and safer use and end-of-life by performing timely SbD interventions to reduce hazard, exposure, or both. Early hazard screening is a crucial first step in this process. In this review, for the first time, commonly used in vitro assays are evaluated for their suitability for SbD hazard testing of nanomaterials (NMs). The goal of SbD hazard testing is identifying hazard warnings in the early stages of innovation. For this purpose, assays should be simple, cost-effective, predictive, robust, and compatible. For several toxicological endpoints, there are indications that commonly used in vitro assays are able to predict hazard warnings. In addition to the evaluation of assays, this review provides insights into the effects of the choice of cell type, exposure and dispersion protocol, and the (in)accurate determination of dose delivered to cells on predictivity. Furthermore, compatibility of assays with challenging advanced materials and NMs released from nano-enabled products (NEPs) during the lifecycle is assessed, as these aspects are crucial for SbD hazard testing. To conclude, hazard screening of NMs is complex and joint efforts between innovators, scientists, and regulators are needed to further improve SbD hazard testing.

Published
2023
Full Text
View/download PDF

2. Interaction between a Novel Oligopeptide Fragment of the Human Neurotrophin Receptor TrkB Ectodomain D5 and the C-Terminal Fragment of Tetanus Neurotoxin

Author

Ana Candalija, Thomas Scior, Hans-Richard Rackwitz, Jordan E. Ruiz-Castelan, Ygnacio Martinez-Laguna, and José Aguilera

Subjects
clostridium neurotoxins, neurotrophin receptors, carboxyl-terminal domain of tetanus neurotoxin, brain-derived neurotrophic factor, Organic chemistry, QD241-441
Abstract

This article presents experimental evidence and computed molecular models of a potential interaction between receptor domain D5 of TrkB with the carboxyl-terminal domain of tetanus neurotoxin (Hc-TeNT). Computational simulations of a novel small cyclic oligopeptide are designed, synthesized, and tested for possible tetanus neurotoxin-D5 interaction. A hot spot of this protein-protein interaction is identified in analogy to the hitherto known crystal structures of the complex between neurotrophin and D5. Hc-TeNT activates the neurotrophin receptors, as well as its downstream signaling pathways, inducing neuroprotection in different stress cellular models. Based on these premises, we propose the Trk receptor family as potential proteic affinity receptors for TeNT. In vitro, Hc-TeNT binds to a synthetic TrkB-derived peptide and acts similar to an agonist ligand for TrkB, resulting in phosphorylation of the receptor. These properties are weakened by the mutagenesis of three residues of the predicted interaction region in Hc-TeNT. It also competes with Brain-derived neurotrophic factor, a native binder to human TrkB, for the binding to neural membranes, and for uptake in TrkB-positive vesicles. In addition, both molecules are located together in vivo at neuromuscular junctions and in motor neurons.

Published
2021
Full Text
View/download PDF

3. The State of the Art and Challenges of In Vitro Methods for Human Hazard Assessment of Nanomaterials in the Context of Safe-by-Design

Author

Ruijter, Nienke, primary, Soeteman-Hernández, Lya G., additional, Carrière, Marie, additional, Boyles, Matthew, additional, McLean, Polly, additional, Catalán, Julia, additional, Katsumiti, Alberto, additional, Cabellos, Joan, additional, Delpivo, Camilla, additional, Sánchez Jiménez, Araceli, additional, Candalija, Ana, additional, Rodríguez-Llopis, Isabel, additional, Vázquez-Campos, Socorro, additional, Cassee, Flemming R., additional, and Braakhuis, Hedwig, additional

Published
2023
Full Text
View/download PDF

4. Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry

Author

Balaz D., Wikman-Jorgensen P.E., Galvañ V.G., Rubio-Rivas M., Campo B.M., López M.N., Caleya J.F.L., Huelgas R.G., Fontán P.M.P., Bailón M.M., Fernández-Garcés M., Cruz A.F., García García G.M., Rhyman N., Corral-Gudino L., Rodríguez-Mancheño A.L., De La Chica M.N., García A.T., Alcalá J.N., Jiménez P.D., Royo Trallero L.E., Casanova P.C., Núñez-Cortés J.M., Casas-Rojo J.-M., Corbella X., Homs N., Montero A., Mora-Luján J.M., De Blas P.A., Cañas C.A., Ayuso B., Morejón J.B., Escudero S.C., Frías M.C., Tejido S.C., Pedroche C.D., Simon R.D., Reyne A.G., Veganzones L.I., Huerta L.J., Blanco A.L., Gonzalo J.L., Lora-Tamayo J., Bermejo C.L., De La Calle G.M., Godoy R.M., Perpiña B.O., Ruiz D.P., Fernández M.S., Montes J.T., Bandera V.A., Alegría J.G., Jiménez-García N., Del Pino J.L., Escalante M.D.M., Romero F.N., Rodriguez V.N., Sierra J.O., Casas L.A., De Oña Á.A., Beato R.A., Gonzalo L.A., Muñoz J.A., Amodeo Oblitas C.M., García C.A., Cebrián M.B., Corral J.B., Guerrero M.B., Estrada A.D.B., Moreno M.C., Fernández P.C., Carrillo R., Pérez S.C., Muñoz E.C., Moreno A.D.C., Carvajal M.C.C., De Santos S., Gómez A.E., Carracedo E.F., Jenaro M.M.F.-M., Galeano Valle F., Garcia A., Fernandez-Bravo I.G., Leoni M.E.G., Antúnez M.G., Narciso C.G.S., Gurjian A.A., Ibáñez L.J., Olleros C.L., Mendo C.L., García S.L., Jimeno V.M., Nohales C.M., Ledesma S.M., Míguez A.M., Delgado C.M., Ortega L.O., Sánchez S.P., Virto A.P., Sanz M.T.P., Llorente B.P., Ruiz S.P., Fernández-Llamazares G.S., Macías M.T., Samaniego N.T., Do Rego A.T., Garcia M.V.V., Villarreal G., Etayo M.Z., Suárez A.M.Á., Vergés C.D., Martínez R.F.-M., Aizpuru E.M.F., Carrasco A.G., Amezua C.H., Martínez D.L., López M.M.M., Zapico A.M., Iscar C.O., Casado L.P., Martínez M.L.T., Chamorro L.M.T., Ayala-Gutiérrez M.M., López R.B., Fonseca J.B., Buonaiuto V.A., Martínez L.F.C., Palacios L.C., Muriel C.C., De Windt F., Christophel A.T.F.-T., Ocaña P.G., García J.G., Hurtado Oliver J.A., Jansen-Chaparro S., López-Carmona M.D., Quirantes P.L., Sampalo A.L., Lorenzo-Hernández E., Sevilla J.J.M., Carmona J.M., Pérez-Belmonte L.M., De Pedro I.P., Pineda-Cantero A., Gómez C.R., Ricci M., Cánovas J.S., Troncoso J.Á., Fernández F.A., Quintana F.B., Arenzana C.B., Molina S.C., Candalija A.C., Bengoa G.D., Grela A.G., Hernández A.L., Vidal A.D., Capitán C.F., Iglesias M.F.G., Muñoz B.G., Gil C.R.H., Martínez J.M.H., Hontañón V., Hernández M.J.J., Lahoz C., Calvo C.M., Gutiérrez J.C.M., Prieto M.M., Robles E.M., Saldaña A.M., Fernández A.M., Prieto J.M.M., Mozo A.N., López C.M.O., Peláez E.P., Pampyn M.P., Simón M.A.Q., Ramos J.C., Ruperto L.R., Purificación A.S., Bueso T.S., Torre R.S., Abanedes C.I.S., Tabares Y.U., Mayoral M.V., Manau J.V., Rivera N.A., Vieitez A.C., Beamonte E.D.C., Manglano J.D., Mera I.F., Andreu M.D.M.G., Aseguinolaza M.G., Lezaun C.G., Laorden C.J., Murgui R.M., Sanz M.T.M., Abad M.D.C.B., Romero M.A.F., Castro S.M., Guillan E.M.P., Nuñez M.P., Fontan P.M.P., Yeguas I.A., Gómez J.A., Cuchillo J.B., López I.B., Clotet N.C., Elías A.E.C., Manuel E.C., De Luque C.M.C., Benbunan C.C., Vilan L.D., Hernández C.D., Peralta E.E.D., Pérez V.E., Fernandez-Castelao S., Saavedra M.O.F., Klepzig J.L.G., and Bermúdez M.

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Medicina, Enfermedades infecciosas, comorbidities, Article, corticosteroids, Who recommendations, Prednisone, Internal medicine, D-dimer, medicine, Oxygen saturation (medicine), business.industry, Adrenocortical hormones, COVID-19, General Medicine, Corticosteroides, medicine.disease, Obesity, Comorbidity, nervous system diseases, Spain, Medicine, National registry, business, medicine.drug
Abstract

Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years, p &lt, 0.001), with hypertension (57.0% vs. 47.7%, 0.001), obesity (26.4% vs. 19.3%, 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%, 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7–160) vs. 49.3 (16–109) mg/dL, 0.001), ferritin (791 (393–1534) vs. 470 (236–996) µg/dL, 0.001), D dimer (750 (430–1400) vs. 617 (345–1180) µg/dL, 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101), 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September, 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation &lt, /=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation &lt, /=90%.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results